Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Radiation Oncology
Published in: Radiation Oncology 1/2011

Open Access 01-12-2011 | Study protocol

Feasibility and early clinical assessment of flattening filter free (FFF) based stereotactic body radiotherapy (SBRT) treatments

Authors: Marta Scorsetti, Filippo Alongi, Simona Castiglioni, Alessandro Clivio, Antonella Fogliata, Francesca Lobefalo, Pietro Mancosu, Pierina Navarria, Valentina Palumbo, Chiara Pellegrini, Sara Pentimalli, Giacomo Reggiori, Anna M Ascolese, Antonella Roggio, Stefano Arcangeli, Angelo Tozzi, Eugenio Vanetti, Luca Cozzi

Published in: Radiation Oncology | Issue 1/2011

Login to get access

Abstract

Purpose

To test feasibility and safety of clinical usage of Flattening Filter Free (FFF) beams for delivering ablative stereotactic body radiation therapy (SBRT) doses to various tumor sites, by means of Varian TrueBeam™ (Varian Medical Systems).

Methods and Materials

Seventy patients were treated with SBRT and FFF: 51 lesions were in the thorax (48 patients),10 in the liver, 9 in isolated abdominal lymph node, adrenal gland or pancreas. Doses ranged from 32 to 75 Gy, depending on the anatomical site and the volume of the lesion to irradiate. Lung lesions were treated with cumulative doses of 32 or 48 Gy, delivered in 4 consecutive fractions. The liver patients were treated in 3 fractions with total dose of 75 Gy. The isolated lymph nodes were irradiated in 6 fractions with doses of 45 Gy. The inclusion criteria were the presence of isolated node, or few lymph nodes in the same lymph node region, in absence of other active sites of cancer disease before the SBRT treatment.

Results

All 70 patients completed the treatment. The minimum follow-up was 3 months. Six cases of acute toxicities were recorded (2 Grade2 and 2 Grade3 in lung and 2 Grade2 in abdomen). No patient experienced acute toxicity greater than Grade3. No other types or grades of toxicities were observed at clinical evaluation visits.

Conclusions

This study showed that, with respect to acute toxicity, SBRT with FFF beams showed to be a feasible technique in 70 consecutive patients with various primary and metastatic lesions in the body.
Appendix
Available only for authorised users
Literature
1.
Timmerman RD, Cho LC, et al.: JCO 2007 Stereotactic Body Radiation Therapy in Multiple Organ Sites. J Clin Oncol 2007, 25: 947-952. 10.1200/JCO.2006.09.7469CrossRefPubMed
2.
Timmerman R, Papiez L, McGarry R, et al.: Extracranial stereotactic radioablation: Results of a phase I study in medically inoperable stage I nonsmall cell lung cancer. Chest 2003, 124: 1946-1955. 10.1378/chest.124.5.1946CrossRefPubMed
3.
Timmerman RD, McGarry R, Yiannoutsos C, et al.: Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. J Clin Oncol 2006, 24: 4833-4839. 10.1200/JCO.2006.07.5937CrossRefPubMed
4.
Onishi H, Shirato H, Nagata Y, et al.: Stereotactic Body Radiotherapy (SBRT) for Operable Stage I Non-Small-Cell Lung Cancer: Can SBRT Be Comparable to Surgery? Int J Radiat Oncol Biol Phys 2010, in press.
5.
Hellman S, Weichselbaum RR: Oligometastases. J Clin Oncol 1995, 13: 8-10.PubMed
6.
Wersall PJ, Blomgren H, Lax I, et al.: Extracranial stereotactic radiotherapy for primary and metastatic renal cell carcinoma. Radiother Oncol 2005, 77: 88-95. 10.1016/j.radonc.2005.03.022CrossRefPubMed
7.
Madsen BL, Hsi RA, Pham HT, et al.: Intrafractional stability of the prostate using a stereotactic radiotherapy technique. Int J Radiat Oncol Biol Phys 2003, 57: 1285-1291. 10.1016/S0360-3016(03)00746-6CrossRefPubMed
8.
Miralbell R, Molla M, Arnalte R, et al.: Target repositioning optimization in prostate cancer: Is intensity-modulated radiotherapy under stereotactic conditions feasible? Int J Radiat Oncol Biol Phys 2004, 59: 366-371. 10.1016/j.ijrobp.2003.10.012CrossRefPubMed
9.
Wang L, Jacob R, Chen L, et al.: Stereotactic IMRT for prostate cancer: Setup accuracy of a new stereotactic body localization system. J Appl Clin Med Phys 2004, 5: 18-28. 10.1120/jacmp.2020.21705CrossRefPubMed
10.
Hoyer M, Roed H, Sengelov L, et al.: Phase-II study on stereotactic radiotherapy of locally advanced pancreatic carcinoma. Radiother Oncol 2005, 76: 48-53. 10.1016/j.radonc.2004.12.022CrossRefPubMed
11.
Koong AC, Le QT, Ho A, et al.: Phase I study of stereotactic radiosurgery in patients with locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 2004, 58: 1017-1021. 10.1016/j.ijrobp.2003.11.004CrossRefPubMed
12.
Koong AC, Christofferson E, Le QT, et al.: Phase II study to assess the efficacy of conventionally fractionated radiotherapy followed by a stereotactic radiosurgery boost in patients with locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 2005, 63: 320-323. 10.1016/j.ijrobp.2005.07.002CrossRefPubMed
13.
Rusthoven KE, Kavanagh BD, Cardenes H, et al.: Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases. J Clin Oncol 2009, 27: 1572-8. 10.1200/JCO.2008.19.6329CrossRefPubMed
14.
Otto K: Volumetric modulated arc therapy: IMRT in a single gantry arc. Med Phys 2008, 35: 310-317. 10.1118/1.2818738CrossRefPubMed
15.
Bignardi M, Navarria P, Mancosu P, et al.: Clinical outcome of hypofractionated stereotactic radiotherapy for abdominal lymph node metastases. Int J Radiati Oncol Biol Phys 2010, in press.
16.
Bignardi M, Cozzi L, Fogliata A, et al.: Critical appraisal of volumetric modulated arc therapy in stereotactic body radiation therapy for metastases to abdominal lymph nodes. Int J Radiat Oncol Biol Phys 2009, 75: 1570-1577. 10.1016/j.ijrobp.2009.05.035CrossRefPubMed
17.
Ong C, Palma D, Verbakel W, et al.: Treatment of large stage I-II lung tumors using stereotactic body radiotherapy (SBRT): planning considerations and early toxicity. Radiother Oncol 2010, 97: 431-436. 10.1016/j.radonc.2010.10.003CrossRefPubMed
18.
Vassiliev O, Kry S, Kuban D, et al.: Treatment planning study of prostate cancer intensity modulated radiotherapy with a Varian clinac operated without a flattening filter. Int J Radiat Oncol Biol Phys 2007, 68: 1567-1571. 10.1016/j.ijrobp.2007.04.025CrossRefPubMed
19.
Poenisch F, Titt U, Vassiliev O, et al.: Properties of unflattened photon beams shaped by a multileaf collimator. Med Phys 2006, 33: 1738-1746. 10.1118/1.2201149CrossRef
20.
Vassiliev ON, Kry SF, Chang JY, et al.: Stereotactic radiotherapy for lung cancer using a flattening filter free Clinac. J Appl Clin Med Phys 2009, 10: 2880.CrossRefPubMed
21.
Cashmore J, Ramtohul M, Ford D: Lowering whole body radiation doses in pediatric intensity modulated radiotherapy through the use of unflattened photon beams. Int J Radiat oncol BIol Phys 2011, in press.
22.
Georg D, Knoos T, McClean B: Current status and future perspective of flattening filter free photon beams. Med Phys 2011, 38: 1280-1293. 10.1118/1.3554643CrossRefPubMed
23.
Kragl G, Wetterstedt S, Knausl B, et al.: Dosimetric characteristics of 6 and 10 MV unflattened photon beams. Radiother Oncol 2009, 93: 141-146. 10.1016/j.radonc.2009.06.008CrossRefPubMed
24.
Hrbacek J, Lang S, Kloeck S: Commissioning of photon beams of a flattening filter free linear accelerator and the accuracy of beam modeling using an anisotropic analytical algorithm. Int J Radiat oncol Biol Phys 2011, in press.
25.
Scorsetti M, Fogliata A, Castiglioni S, et al.: Early clinical experience with volumetric modulated arc therapy in head and neck cancer patients. Radiat Oncol 2010, 5: 93. 10.1186/1748-717X-5-93PubMedCentralCrossRefPubMed
26.
Scorsetti M, Navarria P, Mancosu P, et al.: Large volume unresectable locally advances non small cell lung cancer: acute toxicity and initial outcome results with RapidArc. Radiat Oncol 2010, 5: 94. 10.1186/1748-717X-5-94PubMedCentralCrossRefPubMed
27.
Gwynne S, Wills L, Joseph G, John G, Hurt C, et al.: Respiratory Movement of Upper Abdominal Organs and its Effect on Radiotherapy Planning in Pancreatic Cancer. Clin Oncol 2009, 21: 713-719. 10.1016/j.clon.2009.07.015CrossRef
28.
Kubas A, Mornex F, Merle P, et al.: Irradiation of hepatocellular carcinoma: Impact of breathing on motions and variations of volume of the tumor, liver and upper abdominal organs. Cancer Radiother 2008, 12: 768-774.CrossRefPubMed
29.
Dunlap N, Cai J, Beidermann G, et al.: Chest wall volume receiving > 30 Gy predicts risk of severe pain and or rib fracture after lung stereotactic body radiotherapy. Int J Radiat oncol Biol Phys 2009, 76: 796-801.CrossRefPubMed
30.
Fogliata A, Clivio A, Nicolini G, et al.: Intensity modulation with photons for benign intracranial tumours. A planning comparison of volumetric single arc, helical arc and fixed gantry techniques. Radiother Oncol 2008, 89: 254-262. 10.1016/j.radonc.2008.07.021CrossRefPubMed
31.
Ulmer W, Pyyry J, Kaissl W: A 3D photon superposition convolution algorithm and its foundation on results of Monte Carlo calculations. Phys Med Biol 2005, 50: 1767-90. 10.1088/0031-9155/50/8/010CrossRefPubMed
32.
ICRU report 83: Prescribing, recording and reporting Intensity Modulated Photon Beam Therapy (IMRT) (ICRU report 83). Washington, DC: International Commission on Radiation Units and Measurements; 2010.
33.
National Cancer Institute: Cancer Therapy Evaluation Program. Common Terminology Criteria for Adverse Events. Version 3.0. DCTD, NCI, NIH, NHHS 2003. [http://​ctep.​cancer.​gov]
Metadata
Title
Feasibility and early clinical assessment of flattening filter free (FFF) based stereotactic body radiotherapy (SBRT) treatments
Authors
Marta Scorsetti
Filippo Alongi
Simona Castiglioni
Alessandro Clivio
Antonella Fogliata
Francesca Lobefalo
Pietro Mancosu
Pierina Navarria
Valentina Palumbo
Chiara Pellegrini
Sara Pentimalli
Giacomo Reggiori
Anna M Ascolese
Antonella Roggio
Stefano Arcangeli
Angelo Tozzi
Eugenio Vanetti
Luca Cozzi
Publication date
01-12-2011
Publisher
BioMed Central
Published in
Radiation Oncology / Issue 1/2011
Electronic ISSN: 1748-717X
DOI
https://doi.org/10.1186/1748-717X-6-113

Other articles of this Issue 1/2011

Radiation Oncology 1/2011 Go to the issue

Research

Effects of radiation therapy on tissue and serum concentrations of tumour associated trypsin inhibitor and their prognostic significance in rectal cancer patients

Research

Prognosticators and Risk Grouping in Patients with Lung Metastasis from Nasopharyngeal Carcinoma: A more accurate and appropriate assessment of prognosis

Short report

Ionizing radiation and inhibition of angiogenesis in a spontaneous mammary carcinoma and in a syngenic heterotopic allograft tumor model: a comparative study

Research

Acute toxicity in prostate cancer patients treated with and without image-guided radiotherapy

Research

Mechanisms of increased risk of tumorigenesis in Atm and Brca1 double heterozygosity

Short report

Upfront systemic chemotherapy and preoperative short-course radiotherapy with delayed surgery for locally advanced rectal cancer with distant metastases